Rislenemdaz is an experimental, oral NMDA receptor antagonist that was studied for potential uses in treating major depressive disorder (MDD) and Parkinson’s disease. While early phase I trials showed no benefit for Parkinson’s disease symptoms, some positive indications for clinical meaningfulness were seen in phase II studies for depression, suggesting a possible role in treating MDD and treatment-resistant depression (TRD). The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include rislenemdazum, MK-0657 and CERC‑301. Its PubChem CID is 11394238.
Rislenemdaz
| CAS No | 808733-05-3 |
|---|---|
| Molecular Formula | C19H23FN4O2 |
| Molecular Weight | 358.4 g/mol |
| Synonyms | (4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rislenemdaz is an experimental, oral NMDA receptor antagonist that was studied for potential uses in treating major depressive disorder (MDD) and Parkinson's disease.
The listed CAS number is 808733-05-3.
The listed molecular formula is C19H23FN4O2.
The listed molecular weight is 358.4 g/mol.
(4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate.
The source lists rislenemdazum, MK-0657 and CERC‑301.